Phase 2 N=23 Exemestane and Cyclophosphamide for Metastatic Breast Cancer
Metastatic Beast Cancer
Primary: Progression-free Survival (PFS) Rate at 3 Months — 50.1 percent of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=124 Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Phase 3 N=380 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
Phase 2 N=48 Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Breast Cancer
Primary: Median Progression Free Survival (PFS) — 7.2 months
Phase 2 N=83 Eribulin in HER2 Negative Metastatic BrCa
Breast Cancer
Primary: Overall Response Rate (ORR) — 35.6; 13.2 percentage of participants — p=0.42
Phase 1 N=164 BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Neoplasms
Primary: Progression-free Survival (PFS) - Phase II Part — 7.3; 5.6 Months — p=0.9057
Phase 2 N=58 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Breast Cancer
Primary: Objective Response Rate (ORR) by Investigator Assessment — 12.3 percentage of participants
Phase 2 N=183 Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Primary: Phase 1b and Phase 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 3; 3; 90; 82…
Phase 2 N=102 Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Breast Cancer
Primary: Overall Disease Response Rate — 0; 0; 1; 1 Participants
Phase 2 N=32 Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
Breast Cancer
Primary: Clinical Benefit Rate of the Combination of Enzalutamide/ Fulvestrant — 7 Participants
Phase 2 N=144 A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast Neoplasms
Primary: Stage 1: Percentage of Participants With Objective Response — 10.0; 10.0; 26.9; 16.7 percentage of participants
Phase 2 N=56 Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Breast Neoplasms
Primary: Part I Only: Clinical Benefit Rate (CR+PR+SD≥6months) of Patients Who Received Neratinib Alone — 5 Participants
Phase 2 N=55 T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
HER2-positive Breast Cancer · Breast Cancer · Breast Cancer Stage
Primary: Estimate Progression-free Survival — 16.9; 8.3 Months
Phase 2 N=140 HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Breast Cancer
Primary: Objective Response Rate Per Composite Response Criteria — 7.5; 48.6; 33.3 percent of participants
Phase 2 N=26 Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Breast Cancer
Primary: Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen. — 14.3 months
Phase 3 N=652 Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
Breast Cancer
Primary: Progression Free Survival (PFS) at the Time of Primary Results — 8.97; 11.30; 9.13; 13.63 Months — p=0.0010
Phase 1 N=35 Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLT) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 2 participants
Phase 2 N=52 Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
Breast Cancer
Primary: Objective Response Rate — 71.2 Percentage of participants
Phase 2 N=58 Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer
Breast Cancer
Primary: Progression-free Survival (PFS) Until First Progression — 2.0; 5.7 months
Phase 2 N=18 Herceptin and GM-CSF for Metastatic Breast Cancer
Breast Cancer
Primary: Number of Participants With Tumor Response (Stable Disease) — 5 participants
Phase 2 N=70 Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer
Breast Cancer · Metastasis
Primary: Number of Participants With Objective Response — 0; 1; 1; 1 participants
Phase 2 N=104 MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
Breast Cancer Metastatic
Primary: Clinical Benefit Rate at 24 Weeks — 3; 18; 9 Participants
Phase 2 N=61 Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
HER2-positive Breast Cancer · Male Breast Cancer · Recurrent Breast Cancer
Primary: Objective Response for HER2+ Patients (Best Objective Response a Patient Has Ever Experienced on Study) — 3; 13; 10; 11 Participants
Phase 2 N=151 Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer
Breast Neoplasms · Breast Cancer · Estrogen-receptor Positive Breast Cancer
Primary: Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 2 N=9 Palbociclib With Everolimus + Exemestane In BC
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast · Hormone Receptor (HR)-Positive Breast Cancer
Primary: Clinical Benefit Rate (CBR) [Phase 2a] — 6 Participants
N/A N=13 Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
Estrogen Receptor-positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Cancer
Primary: Number of Participants With Grade 4 Toxicity
Phase 2 N=37 Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
Phase 2 N=40 DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease
Advanced Breast Cancer · HER2-positive Breast Cancer · Brain Metastases
Primary: 16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1) — 1; 7 Participants
Phase 2 N=28 TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer
Estrogen Receptor Positive Breast Cancer
Primary: Ki67 Expression — 15; 10 Percentage of cells with Ki67 expression — p==0.0023
Phase 3 N=235 Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Post Menopausal Breast Cancer
Primary: Summary of Number of Participants With Treatment Emergent Adverse Events (TEAE) - All Grades — 4; 0; 4; 195 Participants